Time to surgery and survival in breast cancer

BMC Surg. 2022 Nov 11;22(1):388. doi: 10.1186/s12893-022-01835-1.

Abstract

Background: This study aimed to investigate the effect of the time from diagnosis to breast cancer surgery on breast cancer patients' prognosis.

Methods: Of the 1900 patients diagnosed with invasive (stage 1-3) breast cancer who underwent surgery in KUH between 2012 and 2019, 279 patients were enrolled in this study. All patients, including those who received neoadjuvant chemotherapy, were classified as Model 1 subjects, and those who received immediate surgical treatment were classified as Model 2 subjects. We conducted a Cox regression analysis to identify prognostic factors of breast cancer associated with the time from diagnosis to surgery.

Results: The univariate results indicated a sharp drop in both groups' survival rates when the time to surgery was delayed for more than 8 weeks (Model 1 p = 0.000; Model 2 p = 0.001). In the multivariate analysis, the hazard ratio (HR) of Model 1increased (HR = 6.84, 95% CI 1.06-44.25) in response to a delay in surgery of more than 8 weeks. Smoking and the American Joint Committee on Cancer (AJCC) staging system had a negative effect on breast cancer prognosis, while hormone therapy had a positive effect.

Conclusion: For all patients, a delay in breast cancer surgery of more than 8 weeks was inversely associated with survival.

Keywords: Breast cancer; Delayed treatment; Neoadjuvant chemotherapy; Surgery; Time.

MeSH terms

  • Breast Neoplasms* / pathology
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Mastectomy
  • Neoadjuvant Therapy / methods
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies